<DOC>
	<DOCNO>NCT02633007</DOCNO>
	<brief_summary>This study double-blind , randomize , placebo-controlled , 2-period , crossover study evaluate safety PK 3 dos CVT 301 levodopa ( l-dopa ) adult asthma .</brief_summary>
	<brief_title>A Study Safety Pharmacokinetics Levodopa Following Administration CVT 301 ( Levodopa Inhalation Powder ) Adults With Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Eligible subject men woman good general health diagnosis mild moderate asthma ; On stable regimen asthma medication least 30 day prior screen ; Body mass index ( BMI ) 18 32 kg/m2 ; Forced expiratory volume one second ( FEV1 ) ≥60 % predict race , age , sex , height ; FEV1/FVC ( force vital capacity ) ratio ≥70 % . More 2 hospitalization emergency room visit , 3 course systemic steroid past 12 month 1 course within past 8 week respiratory illness ; Asthma exacerbation within 8 week screen ; Unscheduled urgent visit medical facility asthmarelated problem within 8 week screen ; History intubation intensive care unit admission asthma past 5 year ; History chronic obstructive pulmonary disorder ( COPD ) require intermittent continuous use oral inhaled medication therapy within last 3 year ; Renal impairment define calculated creatinine clearance ≤ 80 mL/minute .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>